Pliant Therapeutics, Inc. Common Stock (PLRX)

Price$1.20

Value ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-35.16%

Price vs S&P 500 (4W)0.03%

VGM Score50.89

Market Capitalization$78.02M

All Metrics

Book Value / Share (Quarterly)$2.67

P/TBV (Annual)2.73x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.60

Price vs S&P 500 (YTD)-7.66%

Net Profit Margin (TTM)-2871.17%

EPS (TTM)$-2.43

10-Day Avg Trading Volume0.56M

EPS Excl Extra (TTM)$-2.43

EPS (Annual)$-2.43

ROI (Annual)-82.42%

Net Profit Margin (5Y Avg)-2573.80%

Cash / Share (Quarterly)$2.76

ROA (Last FY)-66.31%

EBITD / Share (TTM)$-2.55

ROE (5Y Avg)-54.77%

Operating Margin (TTM)-3156.66%

Cash Flow / Share (Annual)$-2.09

P/B Ratio0.47x

P/B Ratio (Quarterly)0.47x

Net Income / Employee (Annual)$-3,047,800

EV / Revenue (TTM)11.10x

ROA (TTM)-52.11%

EPS Incl Extra (Annual)$-2.43

Current Ratio (Annual)12.00x

Quick Ratio (Quarterly)16.70x

3-Month Avg Trading Volume0.61M

52-Week Price Return-8.03%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$8.40

P/S Ratio (Annual)49.38x

Asset Turnover (Annual)0.00x

52-Week High$1.95

Operating Margin (5Y Avg)-2871.54%

EPS Excl Extra (Annual)$-2.43

CapEx CAGR (5Y)-24.55%

Tangible BV CAGR (5Y)147.93%

26-Week Price Return-19.23%

Quick Ratio (Annual)11.79x

13-Week Price Return-2.33%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)16.89x

Enterprise Value$55.83M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-17.99%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-10211.14%

Cash / Share (Annual)$3.11

3-Month Return Std Dev43.45%

Net Income / Employee (TTM)$-3,047,800

ROE (Last FY)-82.42%

EPS Basic Excl Extra (Annual)$-2.43

Receivables Turnover (TTM)1.58x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.43

Receivables Turnover (Annual)1.58x

ROI (TTM)-62.89%

P/S Ratio (TTM)15.51x

Pretax Margin (5Y Avg)-2573.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.40

Price vs S&P 500 (52W)-36.24%

Year-to-Date Return3.28%

5-Day Price Return4.13%

EPS Normalized (Annual)$-2.43

ROA (5Y Avg)-45.99%

Net Profit Margin (Annual)-10211.14%

Month-to-Date Return3.28%

Cash Flow / Share (TTM)$-2.74

EBITD / Share (Annual)$-2.55

Operating Margin (Annual)-11654.75%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-53.14%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.43

P/TBV (Quarterly)1.70x

P/B Ratio (Annual)0.41x

Pretax Margin (TTM)-2871.17%

Book Value / Share (Annual)$2.95

Price vs S&P 500 (13W)-12.07%

Beta1.21x

Revenue / Share (TTM)$0.00

ROE (TTM)-69.56%

52-Week Low$1.09

vGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.32est. -0.36

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

2.58

2.55

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PLRXPliant Therapeutics, Inc. Common Stock	C	—	C	$1.20
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing oral therapies for fibrotic diseases. Its lead candidate, bexotegrast, is a small-molecule treatment in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company targets significant unmet needs in fibrosis treatment.